7XE Stock Overview
A health technology company, offers health data platform that detects disease risks.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nightingale Health Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.43 |
| 52 Week High | €4.19 |
| 52 Week Low | €0.97 |
| Beta | 0.70 |
| 11 Month Change | 32.95% |
| 3 Month Change | 105.39% |
| 1 Year Change | 236.27% |
| 33 Year Change | -10.86% |
| 5 Year Change | n/a |
| Change since IPO | -32.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7XE | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0.9% | 0.3% | -0.7% |
| 1Y | 236.3% | 4.7% | 4.0% |
Return vs Industry: 7XE exceeded the German Healthcare industry which returned 4.7% over the past year.
Return vs Market: 7XE exceeded the German Market which returned 4% over the past year.
Price Volatility
| 7XE volatility | |
|---|---|
| 7XE Average Weekly Movement | 12.7% |
| Healthcare Industry Average Movement | 4.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7XE's share price has been volatile over the past 3 months.
Volatility Over Time: 7XE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 81 | Teemu Suna | nightingalehealth.com |
Nightingale Health Oyj, a health technology company, offers health data platform that detects disease risks. The company’s blood analysis technology measures various biomarkers from a single blood sample and identifies personal risks of disease using health data assets. It serves healthcare industry and researchers in Finland, the United Kingdom, rest of Europe, and internationally.
Nightingale Health Oyj Fundamentals Summary
| 7XE fundamental statistics | |
|---|---|
| Market cap | €207.57m |
| Earnings (TTM) | -€18.06m |
| Revenue (TTM) | €3.65m |
56.8x
P/S Ratio-11.5x
P/E RatioIs 7XE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7XE income statement (TTM) | |
|---|---|
| Revenue | €3.65m |
| Cost of Revenue | €884.00k |
| Gross Profit | €2.77m |
| Other Expenses | €20.83m |
| Earnings | -€18.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 20, 2024
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 75.81% |
| Net Profit Margin | -494.23% |
| Debt/Equity Ratio | 1.7% |
How did 7XE perform over the long term?
See historical performance and comparison